Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04823130 · ClinicalTrials.gov registry record · Phase 4
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT04823130 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 54 participants.
The verdict
NCT04823130, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
Primary Objective: \- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: * Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus. * To evaluate the efficacy of dupilumab in AD participants with chronic pruritus. * To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.
Interventions
- DRUG Dupilumab (SAR231893)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04823130
The ClinicalTrials.gov registry entry for NCT04823130 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab (SAR231893) is the first listed.
NCT04823130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04823130 about?
NCT04823130 is a clinical study titled "Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis". Primary Objective: \- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: * Assess change in neuronal architecture following short term treatment with dupilumab a...
What is the current status of trial NCT04823130?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2021-04-22. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT04823130?
The interventions under investigation include: Dupilumab (SAR231893) (DRUG).
Who is sponsoring clinical trial NCT04823130?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.